loading

Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten

pulisher
09:00 AM

Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire

09:00 AM
pulisher
08:32 AM

CORCEPT THERAPEUTICS INCORPORATED (CORT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph

08:32 AM
pulisher
08:29 AM

Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead? - Yahoo Finance

08:29 AM
pulisher
Mar 04, 2026

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics IncorporatedCORT - ChartMill

Mar 04, 2026
pulisher
Mar 04, 2026

Corcept Therapeutics (NASDAQ: CORT) Form 144 lists 20,000-share sale on 03/04/2026 - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 04, 2026
pulisher
Mar 04, 2026

Law Offices of Frank R. Cruz Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action - ChartMill

Mar 04, 2026
pulisher
Mar 04, 2026

Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - PR Newswire

Mar 04, 2026
pulisher
Mar 04, 2026

Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha

Mar 04, 2026
pulisher
Mar 03, 2026

Corcept Therapeutics faces securities lawsuit over FDA rejection By Investing.com - Investing.com Canada

Mar 03, 2026
pulisher
Mar 03, 2026

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.

Mar 03, 2026
pulisher
Mar 03, 2026

[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Corcept (CORT) CEO awarded 460,000 stock options in new grant - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Corcept Therapeutics (CORT) officer awarded stock options on 140,000 shares - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Corcept Therapeutics (CORT) CFO awarded stock options on 140,000 shares - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Corcept Therapeutics (CORT) CSO Hazel Hunt awarded 140,000 stock options - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Corcept (NASDAQ: CORT) grants CBO 140,000 options vesting over four years - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Investors of Corcept Therapeutics, Inc. (CORT) Seeking Recovery - The National Law Review

Mar 03, 2026
pulisher
Mar 03, 2026

CORCEPT THERAPEUTICS INCORPORATED (CORT) DEADLINE ALERT Bernstein Liebhard LLP Reminds Corcept Therapeutics Incorporated Investors of Upcoming Deadline - ACCESS Newswire

Mar 03, 2026
pulisher
Mar 03, 2026

Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); ... - Bluefield Daily Telegraph

Mar 03, 2026
pulisher
Mar 03, 2026

Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Beha - GlobeNewswire

Mar 03, 2026
pulisher
Mar 03, 2026

Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.

Mar 03, 2026
pulisher
Mar 03, 2026

Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire

Mar 03, 2026
pulisher
Mar 03, 2026

Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline - ChartMill

Mar 03, 2026
pulisher
Mar 03, 2026

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated LawsuitCORT - PR Newswire

Mar 03, 2026
pulisher
Mar 03, 2026

CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 03, 2026
pulisher
Mar 03, 2026

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire

Mar 03, 2026
pulisher
Mar 02, 2026

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - Financial Times

Mar 02, 2026
pulisher
Mar 02, 2026

ARDT IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Ardent Health, Inc. Investors to Secure Counsel Before Important March 9 Deadline in Securities Class Action - GlobeNewswire Inc.

Mar 02, 2026
pulisher
Mar 02, 2026

Shareholders who lost money in shares of Corcept - GlobeNewswire

Mar 02, 2026
pulisher
Mar 02, 2026

ROSEN, A LEADING AND RANKED FIRM, Encourages Corcept - GlobeNewswire

Mar 02, 2026
pulisher
Mar 02, 2026

FinancialContentDeadline to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (CORT) is April 21, 2026Contact Kaplan Fox - FinancialContent

Mar 02, 2026
pulisher
Mar 02, 2026

Deadline Approaching: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - FinancialContent

Mar 02, 2026
pulisher
Mar 02, 2026

Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Five9, ... - Bluefield Daily Telegraph

Mar 02, 2026
pulisher
Mar 02, 2026

Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Five9, Inc. (NASDAQ - marketscreener.com

Mar 02, 2026
pulisher
Mar 02, 2026

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Mar 02, 2026
pulisher
Mar 02, 2026

Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Mar 02, 2026
pulisher
Feb 28, 2026

How Relacorilant Setback and Lawsuits Will Impact Corcept Therapeutics’ (CORT) Risk-Reward Profile - simplywall.st

Feb 28, 2026
pulisher
Feb 28, 2026

Corcept Therapeutics Accused of Misleading Investors in Class Action - Intellectia AI

Feb 28, 2026
pulisher
Feb 27, 2026

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Corcept - GlobeNewswire

Feb 27, 2026
pulisher
Feb 27, 2026

Corcept Therapeutics (CORT) Litigation: Hagens Berman - GlobeNewswire

Feb 27, 2026
pulisher
Feb 27, 2026

Canaccord Genuity Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail

Feb 27, 2026
pulisher
Feb 27, 2026

Corcept Therapeutics Lawsuits And CRL Put Relacorilant Story Under Pressure - Yahoo Finance

Feb 27, 2026
pulisher
Feb 27, 2026

What is Corcept Therapeutics Incorporated’s market positionJuly 2025 Summary & Safe Entry Point Identification - mfd.ru

Feb 27, 2026
pulisher
Feb 27, 2026

CORCEPT THERAPEUTICS INCORPORATED (CORT) Stock, Price, News, Quotes, Forecast and Insights - MSN

Feb 27, 2026
pulisher
Feb 27, 2026

Is Corcept Therapeutics (CORT) Pricing Reflect Its Sharp One Year Share Price Decline - Yahoo Finance

Feb 27, 2026
pulisher
Feb 27, 2026

HC Wainwright Analysts Increase Earnings Estimates for CORT - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

TD Asset Management Inc Grows Position in Corcept Therapeutics Incorporated $CORT - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

A Look At Corcept Therapeutics (CORT) Valuation After Relacorilant FDA Setback And New Lawsuits - simplywall.st

Feb 27, 2026
pulisher
Feb 27, 2026

Corcept Therapeutics v. Teva Pharmaceuticals: Going Outside The Label To Show No Direct Infringement - Mondaq

Feb 27, 2026
pulisher
Feb 26, 2026

Corcept (CORT) director exercises options and moves shares to family trusts - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming DeadlinesCORT - PR Newswire

Feb 26, 2026
pulisher
Feb 26, 2026

Corcept Therapeutics (NASDAQ: CORT) Investors Who Have Suffered LossesContact Kaplan Fox before April 21, 2026 Lead Plaintiff Deadline - NewMediaWire

Feb 26, 2026
pulisher
Feb 26, 2026

Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action - The AI Journal

Feb 26, 2026
pulisher
Feb 26, 2026

Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline - ChartMill

Feb 26, 2026
pulisher
Feb 26, 2026

CORT Class Action Alert: Robbins LLP Reminds Investors of - GlobeNewswire

Feb 26, 2026
pulisher
Feb 26, 2026

FY2030 Earnings Forecast for CORT Issued By HC Wainwright - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

CORCEPT THERAPEUTICS INCORPORATED (CORT) SHAREHOLDER ALERT - GlobeNewswire

Feb 26, 2026
pulisher
Feb 26, 2026

Corcept Therapeutics (CORT) Margin Compression Reinforces Bearish Narrative Despite FY 2025 Revenue Strength - simplywall.st

Feb 26, 2026
pulisher
Feb 25, 2026

CORT Investors Deadline Alert: Kaplan Fox Announces Corcept Therapeutics, Inc. Securities Class Action FiledLead Plaintiff Deadline April 21, 2026 - NewMediaWire

Feb 25, 2026
pulisher
Feb 25, 2026

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire

Feb 25, 2026
pulisher
Feb 25, 2026

Corcept Therapeutics Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 25, 2026
pulisher
Feb 25, 2026

Corcept Therapeutics Balances Growth With Rising Risks - TipRanks

Feb 25, 2026
pulisher
Feb 25, 2026

INVESTOR DEADLINE: Corcept Therapeutics Incorporated (CORT) Investors with Substantial Losses Have Opportunity to Lead the Corcept Class Action Lawsuit – RGRD Law - marketscreener.com

Feb 25, 2026
$46.72
price down icon 0.50%
$29.17
price down icon 0.98%
$57.77
price down icon 0.03%
$103.05
price down icon 0.96%
$146.31
price down icon 1.82%
biotechnology ONC
$296.81
price down icon 0.57%
Kapitalisierung:     |  Volumen (24h):